Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
85.28
-1.90 (-2.18%)
At close: Mar 3, 2026, 4:00 PM EST
85.17
-0.11 (-0.13%)
Pre-market: Mar 4, 2026, 6:05 AM EST
Edwards Lifesciences Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Edwards Lifesciences stock have an average target of 96.47, with a low estimate of 81 and a high estimate of 110. The average target predicts an increase of 13.12% from the current stock price of 85.28.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edwards Lifesciences stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 6 | 7 | 7 |
| Buy | 5 | 6 | 6 | 7 | 7 | 7 |
| Hold | 6 | 7 | 7 | 7 | 7 | 7 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 19 | 20 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $108 → $95 | Strong Buy | Maintains | $108 → $95 | +11.40% | Feb 11, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $98 → $100 | Buy | Reiterates | $98 → $100 | +17.26% | Feb 11, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $92 → $89 | Hold | Maintains | $92 → $89 | +4.36% | Feb 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $96 → $100 | Buy | Maintains | $96 → $100 | +17.26% | Feb 11, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $103 | Strong Buy | Reiterates | $103 | +20.78% | Feb 11, 2026 |
Financial Forecast
Revenue This Year
6.87B
from 6.07B
Increased by 13.19%
Revenue Next Year
7.54B
from 6.87B
Increased by 9.81%
EPS This Year
2.97
from 1.83
Increased by 62.21%
EPS Next Year
3.29
from 2.97
Increased by 10.60%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 7.1B | 7.9B | |||
| Avg | 6.9B | 7.5B | |||
| Low | 6.4B | 7.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.8% | 14.9% | |||
| Avg | 13.2% | 9.8% | |||
| Low | 5.5% | 2.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.28 | 3.60 | |||
| Avg | 2.97 | 3.29 | |||
| Low | 2.33 | 2.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 78.7% | 21.1% | |||
| Avg | 62.2% | 10.6% | |||
| Low | 27.3% | -11.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.